Sue Dillon, PhD is President and CEO of Aro Biotherapeutics, focused on developing and commercializing Centyrins, a proprietary protein drug platform designed to create bi-specific targeting and to enable cell and tissue – specific delivery of nucleic acids, genetic medicines and other complex drug payloads for cancer and other serious diseases.

Dr. Dillon was Global Therapeutic Area Head for Immunology at Janssen/J&J for 16+years where she led global Immunology R&D and achieved numerous regulatory approvals for innovative antibody products for autoimmune diseases that delivered combined end-user sales in excess of $10 billion.

Sue was named by FierceBiotech as one of the “Top Women in Biotech”, and serves on the Board of Directors of the prestigious Wistar Institute.